THE CLINICAL material incorporated in this paper is the product of a cooperative effort by representatives of the largest eye clinics in the Chicago metropolitan area who, at the instigation of the Chicago Ophthalmological Society, agreed to pool their initial experiences with the use of pituitary adrenocorticotropic hormone (ACTH) and cortisone (11-dehydro-17-hydroxycorticosterone) in ophthalmic diseases in order to obtain a more comprehensive understanding of the use, indications and therapeutic spectrum of these agents. The information here contained is presented primarily from the point of view of practical clinical ophthalmology, without reference to favorable or unfavorable effects on associated systemic diseases or to any unfavorable physical or mental alterations for which the therapeutic agent might be held responsible. Each clinic reported its total experiences with these drugs. Consequently, although the bulk of the cases belong in those categories where the available literature indicates one might expect fruitful results, there are in
FITZGERALD JR, BELLOWS JG, DONEGAN JM, et al. EARLY CLINICAL RESULTS OF ACTH AND CORTISONE TREATMENT OF OCULAR DISEASES. AMA Arch Ophthalmol. 1951;45(3):320–333. doi:10.1001/archopht.1951.01700010326007
Monkeypox Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.